


Glecirasib

Chemical Properties

CAS No. :	2657613-87-9
Formula:	C ₃₁ H ₂₆ ClF ₄ N ₇ O ₂
Molecular Weight:	640.03
Storage:	Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i>



Biological Description

Description	Glecirasib (JAB-21822) is an orally active KRAS G12C inhibitor that selectively binds to and suppresses the activity of KRAS G12C mutant proteins, thereby inhibiting KRAS G12C-dependent signaling pathways. Glecirasib exhibits high selectivity, potent inhibition, and favorable safety, and is primarily used in studies of non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
Targets(IC50)	Ras,Kras
In vitro	Methods: KRAS G12C mutant cells were treated with a gradient concentration of Glecirasib and cetuximab in combination for 6 days, followed by cell viability assessment using the CellTiter-Glo assay. Results: A significant synergistic effect was observed in colorectal cancer cells when Glecirasib combined with cetuximab. [1]
In vivo	Methods: Glecirasib (10 mg/kg, oral, once a day, 3 weeks) was used to treat NCI-H1373 xenograft mice, and the tumor growth and body weight growth in the mice were observed. Results: Glecirasib inhibited tumor growth in the NCI-H1373 xenograft mouse model and had no significant effect on the body weight of the mice, indicating high safety. [1-

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.5624 mL	7.8121 mL	15.6243 mL
5 mM	0.3125 mL	1.5624 mL	3.1249 mL
10 mM	0.1562 mL	0.7812 mL	1.5624 mL
50 mM	0.0312 mL	0.1562 mL	0.3125 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Wang P, et al. Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312. *Cancer Res Commun.* 2025 May 1;5(5):792-803.

Li J, Shen L, Gu Y, et al. Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors[J].

Ma C, et al. Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment. *J Med Chem.* 2024 Aug 22;67(16):13534-13549.

Fuerst M L. Glecirasib Induces Promising Efficacy in Patients With Advanced Lung Cancer[J].

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481